Drug research

Azetukalner

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as XEN1101

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
A Randomized Study of Azetukalner Versus Placebo in Major Depressive DisorderNCT06775379	XENE	Phase 3	Recruiting	2026-08Estimated
An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE)NCT07217860	XENE	Phase 3	Enrolling by invitation	2029-06Estimated
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)NCT07076407	XENE	Phase 3	Recruiting	2027-05Estimated
An Open-Label Study of Azetukalner in Major Depressive DisorderNCT06922110	XENE	Phase 3	Enrolling by invitation	2027-01Estimated
A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)NCT07172516	XENE	Phase 3	Recruiting	2028-06Estimated

XENERecruitingPrimary completion: 2026-08 · Estimated

Trial details

XENEEnrolling by invitationPrimary completion: 2029-06 · Estimated

Trial details

XENERecruitingPrimary completion: 2027-05 · Estimated

Trial details

XENEEnrolling by invitationPrimary completion: 2027-01 · Estimated

Trial details

XENERecruitingPrimary completion: 2028-06 · Estimated

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.